Updates are available Correction dated 2024-10-17
Click to view Correction: https://doi.org/10.1186/s12943-024-02152-2
-
Authors
Montégut, Léa
Liu, Peng
Zhao, Liwei
Pérez-Lanzón, María
Chen, Hui
Mao, Misha
Zhang, Shuai
Derosa, Lisa
Naour, Julie Le
Lambertucci, Flavia
Mingoia, Silvia
Nogueira-Recalde, Uxía
Mena-Osuna, Rafael
Herranz-Montoya, Irene
Djouder, Nabil
Baulande, Sylvain
Pan, Hui
Joseph, Adrien
Messaoudene, Meriem
Routy, Bertrand
Fidelle, Marine
Ben Ahmed, Tarek
Caron, Olivier
Busson, Pierre
Boulate, David
Deschasaux-Tanguy, Mélanie
Arnault, Nathalie
Pol, Jonathan G.
Piaggio, Eliane
Touvier, Mathilde
Zitvogel, Laurence
Delaloge, Suzette
Martins, Isabelle
Kroemer, Guido
-
Funding
Funding for this research was provided by:
China Scholarship Council
Erasmus+
Xunta de Galicia (IN606B-2021/015)
Ministerio de Ciencia, Innovación y Universidades (FPU17/04473)
Agencia Estatal de Investigación (https://doi.org/10.13039/501100011033)
Ministerio de Ciencia e Innovación (PID2021-122695OB-I00)
European Regional Development Fund
Odyssea Association
Agence Nationale de la Recherche
Ligue Contre le Cancer
Institut National Du Cancer
Institut Gustave-Roussy
Association pour la Recherche sur le Cancer
Cancéropôle Ile de France
Fondation pour la Recherche Médicale
Elior
European Joint Programme on Rare Diseases Wilsonmed
European Research Council
Hevolution Network on Senescence in Aging
Institut Universitaire de France
Mark Foundation For Cancer Research
Seerave Foundation
Alliance Nationale pour les Sciences de la Vie et de la Santé
- License Information
-
More Information
Article History
Received: 27 May 2024
Accepted: 21 August 2024
First Online: 6 September 2024
Change Date: 17 October 2024
Change Type: Update
Change Details: Following publication of the original article [1], the authors noticed a minor but significant error in the representation of the author name Tarek Ben Ahmed as “Ben” was captured as given name instead of a family name. Thus, in the online version, the name Tarek Ben Ahmed was mistakenly listed as Ahmed TB instead of Ben Ahmed T.
Change Date: 17 October 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12943-024-02152-2
Declarations
:
: The clinical trials (NCT00272428 and NCT01464086) were registered and approved by regular authorities as indicated in the Materials and Methods. Animal experimentation was approved by the local ethics committee at Cordeliers Research Center (project numbers #24410, #31018).
: GK have been holding research contracts with Daiichi Sankyo, Eleor, Kaleido, Lytix Pharma, PharmaMar, Osasuna Therapeutics, Samsara Therapeutics, Sanofi, Tollys, and Vascage. GK is on the Board of Directors of the Bristol Myers Squibb Foundation France. GK is a scientific co-founder of everImmune, Osasuna Therapeutics, Samsara Therapeutics and Therafast Bio. GK is in the scientific advisory boards of Hevolution, Institut Servier, Longevity Vision Funds and Rejuveron Life Sciences. GK is the inventor of patents covering therapeutic targeting of aging, cancer, cystic fibrosis and metabolic disorders. One of these patents (co-invented by LM and IM) deals with the use of ACBP/DBI neutralisation for the treatment of cancer. GK’s brother, Romano Kroemer, was an employee of Sanofi and now consults for Boehringer-Ingelheim. IM is a consultant for Osasuna Therapeutics. LZ has held research contracts with Glaxo Smyth Kline, Incyte, Lytix, Kaleido, Innovate Pharma, Daiichi Sankyo, Pilege, Merus, Transgene, 9 m, Tusk and Roche, was on the on the Board of Directors of Transgene, is a cofounder of everImmune, and holds patents covering the treatment of cancer and the therapeutic manipulation of the microbiota. The funders had no role in the design of the study; in the writing of the manuscript, or in the decision to publish the results. The other authors declare no conflicts of interest.
